Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Gabitzsch is the Vice-President, Research for the Etubics Corporation where she assumes the overall responsibility for the pre-clinical research and development of novel vaccines to treat cancers and infectious diseases. Under her leadership, the company has advanced from pre-clinical studies to clinical trials for a colorectal product. She has also brought the Company’s human E.C7 manufacturing cell line to the GMP Master Cell Bank stage and is a collaborator on several NIH funded grants exceeding millions of dollars in funding. Ms. Gabitzsch received academic training in microbiology, chemistry and immunology at Colorado State University. She is the leader in the peer reviewed publication of the studies that put forth the scientific basis for the Company’s technology. Her publications include advancing the development of vaccines against infectious agents such as HIV-1 and H1N1 and immunotherapeutic applications of the Etubics Platform against breast and colorectal cancers. Ms. Gabitzsch also presents the Company’s findings at domestic and international meetings. Before joining the Etubics Corporation, she was previously at the Centers for Disease Control and Prevention (CDC) in the Division of Vector-borne and Infectious Diseases (DVBID). While at the CDC, Ms. Gabitzsch was a recipient of an Oak Ridge Institute of Science fellowship. Her areas of research focused on bacterial and viral vector-borne pathogens.